



## UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

			\D_
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
2° 2°° 2 2 2 20 2°°			

09/409,800

09/30/99

BLATTNER

1

960296.95939

HM22/0801

NICHOLAS J SEAY QUARLES & BRADY LLP PO BOX 2113 MADISON WI 53701-2113 DEVI, S

ART UNIT PAPER NUMBER

1645

DATE MAILED:

**EXAMINER** 

08/01/00

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

### Office Action Summary

Application No.

Applicant(s)

09/409,800

S. Devi, Ph.D.

Examiner

Blattner et al.

Group Art Unit 1645



Responsive to communication(s) filed on 03/03/2000.	·
This action is <b>FINAL</b> .	:
Since this application is in condition for allowance except for formal in accordance with the practice under Ex parte Quayle, 1935 C.D.	11; 453 U.G. 213.
A shortened statutory period for response to this action is set to expire s longer, from the mailing date of this communication. Failure to responsible to become abandoned. (35 U.S.C. § 133). Extensions of to CFR 1.136(a).	ond within the period for response will cause the
Disposition of Claims	
X Claim(s) 1-11	jare pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	is/are allowed.
Claim(s)	is/are rejected.
☐ Claim(s)	is/are objected to.
☐ Claim(s)	are subject to restriction or election requirement.
IXI Claims 1-11	
Application Papers  See the attached Notice of Draftsperson's Patent Drawing Revie The drawing(s) filed on is/are objected to	by the Examiner.
<ul><li>☐ The proposed drawing correction, filed on</li><li>☐ The specification is objected to by the Examiner.</li><li>☐ The oath or declaration is objected to by the Examiner.</li></ul>	
Priority under 35 U.S.C. § 119  Acknowledgement is made of a claim for foreign priority under All Some* None of the CERTIFIED copies of the preceived. received in Application No. (Series Code/Serial Number) received in this national stage application from the International Stage app	priority documents have been national Bureau (PCT Rule 17.2(a)).
Attachment(s)	
<ul> <li>Notice of References Cited, PTO-892</li> <li>□ Information Disclosure Statement(s), PTO-1449, Paper No(s).</li> <li>□ Interview Summary, PTO-413</li> <li>□ Notice of Draftsperson's Patent Drawing Review, PTO-948</li> <li>□ Notice of Informal Patent Application, PTO-152</li> <li>☑ Notice of Comply with Sequence Aules.</li> </ul>	
SEE OFFICE ACTION ON THE F	OLLOWING PAGES

Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLIC	CANT A	TTORNEY DOCKET NO.
09/409,800	09/30/99	Blatter et al.		960296-95939
	-	1		
			EXA	AMINER
			S. I	Devi, Ph.D.
			ART UNIT	PAPER NUMBER
			1645	6
		DATE	E MAILED:	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

- 1) This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.
- 2) APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD OF TIME FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R 1.821 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R 1.821(g). Extensions of time may be obtained under the provisions of 37 C.F.R 1.136. In no case may an Applicant extend the period of reply beyond the SIX MONTH statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Serial Number 09/409,800 Art Unit: 1645

#### **Species Election**

- 3) Claims 1-11 are under prosecution.
- Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-305-3704. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Paula Hutzell, Ph.D., Supervisory Patent Examiner at Paula.Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.
- 5) The instant application contains claims directed to patentably distinct species of the claimed invention. Election to one of the ORF polynucleotide species, which are structurally distinct from one another, is required:
- I. (a) ORF4; (b) ORF17; (c) ORF18; (d) ORF21; (e) ORF 72 and (f) ORF 74a in claims 1 and 2.
- II. (a) ORF42; (b) ORF43; (c) ORF44; (d) ORF5; (e) ORF 59; (f) ORF60; (g) ORF61; (h) ORF73; (i) ORF74; (j) ORF84 and (k) ORF85 in claims 5 and 6.

Election to one of the open reading frame species contained in a recombinant DNA construction is required:

- (a) Y004; (b) Y005 and (c) Y0007 in claims 9 and 10.
- Applicants are required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.
- 7) Applicants are advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 8) Should Applicants traverse on the ground that the species are not patentably distinct,
  Applicants should submit evidence or identify such evidence now of record showing the species to

Serial Number 09/409,800

Art Unit: 1645

be obvious variants or clearly admit on the record that this is the case. In either instance, if the Examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- Applicants are reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filled petition under CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).
- 10) Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (703) 308-9347. The Examiner can normally be reached on Monday to Friday from 7.45 a.m. to 4.15 p.m. A telephone message may be left on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Lynette Smith, can be reached on (703) 308-3909. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

S. Devi July 2000



DATE.

# RESTRICTION ELECTION FACSIMILE TRANSMISSION

FROM/ATTORNEY	·:
FIRM:	
PAGES, INCLUDIN	IG COVERSHEET:
PHONE NUMBER:	
TO EXAMINER:	
ART UNIT:	
SERIAL NUMBER:	
FAX/TELECOPIER	NUMBER: (703) 308-4315
PLEASE NOTE:	THIS FACSIMILE NUMBER IS TO BE USED ONLY FOR RESPONSES TO RESTRICTIONS.
COMMENTS:	

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.

Application No.: 09/409,800

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	<ol> <li>This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Аp	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	questions regarding compliance to these requirements, please contact:
Foi Foi	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 tentIn Software Program Support (SIRA) Technical Assistance
	To Purchase Patentin Software 703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE